A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms MAGNOLIA
- Sponsors BeiGene
- 12 Nov 2019 According to a BeiGene media release, the company expects to complete the enrollment in 2019 or early 2020.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 19 Feb 2019 According to a BeiGene media release, the first patient has been dosed in this study.